Why might a pediatric patient be prescribed Lancora (ivabradine)?

Pediatric Prescription of Lancora (Ivabradine)

A pediatric patient would be prescribed Lancora (ivabradine) primarily for heart rate control in two clinical scenarios: symptomatic heart failure with reduced ejection fraction (HFrEF) or treatment-resistant focal atrial tachycardia, particularly when conventional antiarrhythmics have failed.

Primary Indications in Pediatric Patients

Heart Failure with Reduced Ejection Fraction

While the adult guidelines 1, 2, 1 establish ivabradine for HFrEF (LVEF ≤35%, heart rate ≥70 bpm, NYHA class II-III), pediatric use follows similar principles but with important adaptations. The medication selectively inhibits the If current in the sinoatrial node, reducing heart rate without negative effects on myocardial contractility or blood pressure 3.

Key prescribing criteria for pediatric HFrEF:

• Patient must be in stable sinus rhythm
• Already receiving maximum tolerated beta-blocker therapy (this is critical—beta-blockers must be optimized first due to proven mortality benefits) 4, 2
• Persistent elevated heart rate despite beta-blocker therapy
• Symptomatic with evidence of reduced cardiac output

Focal Atrial Tachycardia (Emerging Pediatric Use)

This represents the most compelling recent evidence for pediatric ivabradine use. Recent pediatric studies demonstrate ivabradine's effectiveness when conventional antiarrhythmics fail 5, 6, 7.

Specific pediatric arrhythmia indications:

• Focal atrial tachycardia resistant to conventional therapy 6: Ivabradine achieved rhythm or heart rate control in 50% of pediatric patients within 48 hours at doses of 0.1-0.2 mg/kg every 12 hours
• Tachycardia-induced cardiomyopathy (TIC): Particularly valuable when left ventricular dysfunction is present (LVEF <50%, LVDD z-score >2) 6
• Incessant atrial tachycardia post-cardiac surgery 7: Case reports show successful conversion when multiple standard therapies (adenosine, amiodarone, cardioversion, beta-blockers, digoxin) have failed
• Third-line antiarrhythmic therapy 5: Most commonly used after first- and second-line agents prove inadequate

Hypertrophic Cardiomyopathy (Specialized Use)

In neonates with severe hypertrophic cardiomyopathy (particularly Noonan syndrome-related), ivabradine provides heart rate control without worsening left ventricular outflow tract obstruction—a critical advantage over beta-blockers and calcium channel blockers that can compromise hemodynamics 8.

Dosing in Pediatric Patients

Initial dosing strategy 5, 6:

• Start at 0.05-0.1 mg/kg/dose every 12 hours with meals
• Titrate to 0.2 mg/kg/dose every 12 hours if inadequate response after 48 hours
• Median effective doses range from 0.05-0.07 mg/kg/dose
• For patients ≥75 years or with conduction defects, start at 2.5 mg twice daily 4

Critical Clinical Considerations

When Ivabradine Should NOT Be Used

• Patients NOT in sinus rhythm (persistent/chronic atrial fibrillation, 100% atrial pacing) 4
• History of angioedema 1, 2, 1
• Concomitant use with diltiazem or verapamil 3
• Recent myocardial infarction (within 2 months) 1

Feeding Status Consideration

Important practical point: 58.8% of pediatric patients in one study received ivabradine successfully despite not being on full enteral feeds 5, suggesting partial feeding is not an absolute contraindication, though optimal absorption occurs with meals.

Drug Interactions

• 94.1% of pediatric patients had Class C drug interactions 5
• Avoid strong CYP3A4 inhibitors that can increase ivabradine levels and cause excessive bradycardia 3
• Cannot be combined with diltiazem or verapamil 3

Adverse Effects to Monitor

• Bradycardia: <100 bpm in neonates, <50 bpm in older children 5
• Visual phosphenes: Occur in 5.4% of patients, usually mild and transitory, rarely requiring discontinuation (<1%) 3
• Atrial fibrillation: Absolute increase of 0.7%, mostly paroxysmal 3
• Emesis attributed to medication 5

Clinical Outcomes

For arrhythmias: 50% of pediatric patients achieved rhythm or heart rate control within 48 hours 6, with 58.8% discharged home on ivabradine for chronic therapy 5. Only one patient (20%) experienced breakthrough tachycardia requiring addition of metoprolol during median 5-month follow-up 6.

For heart failure: Reduces HF hospitalizations without mortality benefit 1, 2, 1. The primary benefit is symptom control and reduced hospitalization, not survival improvement.

Algorithmic Approach to Prescribing

1. Confirm diagnosis: HFrEF with persistent tachycardia OR treatment-resistant focal atrial tachycardia
2. Verify sinus rhythm: Must be present; paroxysmal AF history acceptable if sinus rhythm >40% of time 4
3. Optimize beta-blocker first (for HFrEF): Titrate to maximum tolerated dose before considering ivabradine 4, 2
4. Check heart rate: Must be ≥70 bpm at rest for HFrEF indication 1, 4, 2, 1
5. Screen for contraindications: Angioedema history, concomitant diltiazem/verapamil, unstable status
6. Initiate at 0.1 mg/kg every 12 hours with meals 5, 6
7. Assess response at 48 hours: If inadequate, increase to 0.2 mg/kg every 12 hours 6
8. Monitor for bradycardia and visual symptoms during titration

Bottom line: Ivabradine in pediatrics is primarily reserved for heart rate control in symptomatic HFrEF already on optimal beta-blockade, or as rescue therapy for focal atrial tachycardia when conventional antiarrhythmics fail, with emerging evidence supporting its safety and efficacy in both scenarios.